Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company's ZUNVEYL (benzgalantamine) product is a delayed release oral tablet formulation indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. Its pre-clinical development programs include ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mTBI; ALPHA-0602; ALPHA-0702 & ALPHA-0802 (Progranulin and Progranulin GEM’s) for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis or Lou Gehrig’s disease and spinal muscular atrophy, and ALPHA-1062 for the treatment of acute pancreatitis.
종목 코드 ACOG
회사 이름Alpha Cognition Inc
상장일Jun 09, 2021
CEOMcfadden (Michael E)
직원 수52
유형Ordinary Share
회계 연도 종료Jun 09
주소c/o 1200 - 750 West Pender Street
도시VANCOUVER
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가Canada
우편 번호V6C 2T8
전화16045649244
웹사이트https://www.alphacognition.com/
종목 코드 ACOG
상장일Jun 09, 2021
CEOMcfadden (Michael E)
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음